Jun 24, 2019
FSD Pharma Receives Full “Sale for Medical Purposes” Cannabis License from Health Canada
Apr 23, 2019
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
Dec 21, 2018
Therapix Biosciences Terminates FSD Acquisition Letter of Intent
Dec 11, 2018
Therapix Biosciences Provides Update Regarding FSD Acquisition
Oct 14, 2018
FSD Pharma and SciCann Therapeutics to Attend the CannX International Medical Cannabis Convention in Tel Aviv Israel
Oct 10, 2018
FSD Pharma Congratulates High Tide Inc. for Closing Oversubscribed Private Placement and Announces $2 Million Lead Order
Oct 09, 2018
FSD Pharma Begins Construction of Heritage Museum and Flagship Dispensary in Ontario
Sep 27, 2018
FSD Pharma welcomes legislation to allow private retail of cannabis in Ontario
Sep 27, 2018
FSD Pharma Added to Leading Cannabis ETF With Significant 1.9% Weighting
Sep 25, 2018
FSD Pharma Receives First Delivery of Cantabb Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets Per Day
Sep 23, 2018
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
Sep 19, 2018
FSD Pharma Announces Upgraded Listing to OTCQB Venture Market
Sep 18, 2018
FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms
Sep 17, 2018
FSD Pharma joins Snipp's Cannabis Marketing Resource Center
Sep 12, 2018
FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
Sep 11, 2018
FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
Aug 21, 2018
FSD Pharma Completes Harvest and Microbial Testing of First Lot
Jul 23, 2018
FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer
Jul 19, 2018
FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures